OpenDNA has officially launched TotalRisk+ – an advanced AI-based genetic test designed to assess an individual’s risk across multiple cancer types in a single analysis. This innovative solution is built on polygenic risk scores (PRS), combining the power of genomic data and machine learning to help identify those at elevated cancer risk earlier and more accurately.
TotalRisk+ covers a broad spectrum of hereditary and common cancers including breast, prostate, ovarian, colorectal, and lung cancers. With a simple genetic test, patients and clinicians can access personalized risk profiles that inform earlier screening, lifestyle changes, or preventive therapies.
“We are excited to introduce TotalRisk+, our latest genetic screening solution for cancer risk,” said Dr. Eran Feldhay, CEO and Founder of OpenDNA. “By leveraging the power of AI and comprehensive polygenic analysis, TotalRisk+ empowers individuals and their physicians with personalized insights that can guide proactive health decisions and potentially save lives.”
TotalRisk+ is designed for clinical use and processed through OpenDNA’s secure, cloud-based platform. Results are delivered in an accessible, physician-ready format that integrates easily into care workflows. With cancer still among the leading causes of death globally, OpenDNA’s TotalRisk+ test brings new possibilities for early detection, personalized prevention, and smarter healthcare delivery.
